

# EURO-EWING 99: European ewing tumour working initiative of national groups

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 29/10/2021	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-treatment-for-patients-with-ewings-sarcoma-or-peripheral-primitive-neuroectodermal-tumour>

## Study website

<http://www.birmingham.ac.uk/research/activity/mds/trials/crcu/trials/ee99/index.aspx>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Bernadette Brennan

### Contact details

Royal Manchester Children's Hospital  
Oxford Road  
Manchester  
United Kingdom  
M13 9WL

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00020566

Secondary identifying numbers

## Study information

### Scientific Title

Combination chemotherapy with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma

### Acronym

EURO-EWING 99

### Study objectives

This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.

Please note as of 08/02/2011 the anticipated end date for this trial has been updated from 31/03/2010 to 30/03/2017.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Ewing's sarcoma

### Interventions

Three randomisations, two arms per randomisation:

Randomisation 1: vincristine, dactinomycin, and ifosfamide (VAI) versus vincristine,

dactinomycin, and cyclophosphamide (VAC)

Randomisation 2 (loc): VAI versus busulfan, melphalan (Bu-Mel)

Randomisation 2 (pulm): VAI and lung radiation versus Bu-Mel (NO lung radiation)

## **Intervention Type**

Drug

## **Phase**

Phase III

## **Drug/device/biological/vaccine name(s)**

Vincristine, dactinomycin, ifosfamide, cyclophosphamide, busulfan, melphalan

## **Primary outcome measure**

1. Event-free survival
2. Overall survival

## **Secondary outcome measures**

1. Feasibility, toxicity, and response at one month following induction therapy
2. Feasibility and toxicity of consolidation regimens at one month following consolidation therapy

## **Overall study start date**

01/02/2001

## **Completion date**

30/03/2017

# **Eligibility**

## **Key inclusion criteria**

1. Histologically confirmed Ewing's tumour of the bone or soft tissue
2. Age less than 50
3. Completed pre-treatment investigations allowing prognostic group definition
4. No previous chemotherapy
5. Informed consent
6. Normal cardiac and renal function
7. Interval between date of definitive biopsy and registration less than 45 days
8. Interval between date of definitive biopsy and start of chemotherapy less than 30 days

## **Participant type(s)**

Patient

## **Age group**

Not Specified

## **Sex**

Both

## **Target number of participants**

1200

**Total final enrolment**

1695

**Key exclusion criteria**

Does not comply with above inclusion criteria

**Date of first enrolment**

01/02/2001

**Date of final enrolment**

30/03/2017

## **Locations**

**Countries of recruitment**

Australia

Austria

Belgium

Canada

Denmark

England

France

Germany

Ireland

Netherlands

New Zealand

Portugal

Switzerland

United Kingdom

United States of America

**Study participating centre**

**Cancer Research UK Clinical Trials Unit (CRCTU)**  
University of Birmingham  
Birmingham  
United Kingdom  
B15 2TT

## **Sponsor information**

### **Organisation**

University of Birmingham

### **Sponsor details**

Edgbaston  
Birmingham  
United Kingdom  
B15 2TT

### **Sponsor type**

Charity

### **Website**

<http://www.ukccsg.org>

### **ROR**

<https://ror.org/03angcq70>

## **Funder(s)**

### **Funder type**

Charity

### **Funder Name**

Cancer Research UK

### **Alternative Name(s)**

CR\_UK, Cancer Research UK - London, CRUK

### **Funding Body Type**

Private sector organisation

### **Funding Body Subtype**

Other non-profit organizations

### **Location**

## Results and Publications

### Publication and dissemination plan

Planned publication in a peer reviewed journal.

### Intention to publish date

01/01/2010

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2006		Yes	No
<a href="#">Results article</a>	results	10/07/2010		Yes	No
<a href="#">Results article</a>	results	01/09/2015		Yes	No
<a href="#">Results article</a>	results	01/10/2017		Yes	No
<a href="#">Plain English results</a>		28/03/2019	29/10/2021	No	Yes